Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Simultaneous Versus Sequential Heart-liver Transplantation: Ideal Strategies for Organ Allocation.

Transplantation direct

Rucker AJ, Anderson KL, Mulvihill MS, Yerokun BA, Barbas AS, Hartwig MG.
PMID: 30656213
Transplant Direct. 2018 Dec 19;5(1):e415. doi: 10.1097/TXD.0000000000000854. eCollection 2019 Jan.

BACKGROUND: Simultaneous heart-liver (SHL) transplantation is an efficacious therapeutic modality for patients with combined heart and liver failure. However, the extent to which heart transplantation followed by sequential liver transplantation (LAH) can match the benefit of simultaneous transplantation has...

Cite
Rucker AJ, Anderson KL, Mulvihill MS, et al. Simultaneous Versus Sequential Heart-liver Transplantation: Ideal Strategies for Organ Allocation. Transplant Direct. 2018;5(1):e415doi: 10.1097/TXD.0000000000000854.
Rucker, A. J., Anderson, K. L., Mulvihill, M. S., Yerokun, B. A., Barbas, A. S., & Hartwig, M. G. (2019). Simultaneous Versus Sequential Heart-liver Transplantation: Ideal Strategies for Organ Allocation. Transplantation direct, 5(1), e415. https://doi.org/10.1097/TXD.0000000000000854
Rucker, A Justin, et al. "Simultaneous Versus Sequential Heart-liver Transplantation: Ideal Strategies for Organ Allocation." Transplantation direct vol. 5,1 (2019): e415. doi: https://doi.org/10.1097/TXD.0000000000000854
Rucker AJ, Anderson KL, Mulvihill MS, Yerokun BA, Barbas AS, Hartwig MG. Simultaneous Versus Sequential Heart-liver Transplantation: Ideal Strategies for Organ Allocation. Transplant Direct. 2018 Dec 19;5(1):e415. doi: 10.1097/TXD.0000000000000854. eCollection 2019 Jan. PMID: 30656213; PMCID: PMC6324910.
Copy Download .nbib Format: NLM
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).

medRxiv : the preprint server for health sciences

Murray DD, Babiker AG, Baker JV, Barkauskas CE, Brown SM, Chang CC, Davey VJ, Gelijns AC, Ginde AA, Grund B, Higgs E, Hudson F, Kan VL, Lane HC, Murray TA, Paredes R, Parmar MKB, Pett S, Phillips AN, Polizzotto MN, Reilly C, Sandkovsky U, Sharma S, Teitelbaum M, Thompson BT, Young BE, Neaton JD, Lundgren JD.
PMID: 33215168
medRxiv. 2021 Apr 08; doi: 10.1101/2020.11.08.20227876.

BACKGROUND: Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership initiated the Therapeutics for Inpatients with COVID-19 (TICO). TICO is a multi-arm, multi-stage...

Cite
Murray DD, Babiker AG, Baker JV, et al. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). medRxiv. 2021;doi: 10.1101/2020.11.08.20227876.
Murray, D. D., Babiker, A. G., Baker, J. V., Barkauskas, C. E., Brown, S. M., Chang, C. C., Davey, V. J., Gelijns, A. C., Ginde, A. A., Grund, B., Higgs, E., Hudson, F., Kan, V. L., Lane, H. C., Murray, T. A., Paredes, R., Parmar, M. K. B., Pett, S., Phillips, A. N., Polizzotto, M. N., Reilly, C., Sandkovsky, U., Sharma, S., Teitelbaum, M., Thompson, B. T., Young, B. E., Neaton, J. D., & Lundgren, J. D. (2021). Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.11.08.20227876
Murray, Daniel D, et al. "Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2020.11.08.20227876
Murray DD, Babiker AG, Baker JV, Barkauskas CE, Brown SM, Chang CC, Davey VJ, Gelijns AC, Ginde AA, Grund B, Higgs E, Hudson F, Kan VL, Lane HC, Murray TA, Paredes R, Parmar MKB, Pett S, Phillips AN, Polizzotto MN, Reilly C, Sandkovsky U, Sharma S, Teitelbaum M, Thompson BT, Young BE, Neaton JD, Lundgren JD. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). medRxiv. 2021 Apr 08; doi: 10.1101/2020.11.08.20227876. PMID: 33215168; PMCID: PMC7675662.
Copy Download .nbib Format: NLM
Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation.

The New England journal of medicine

Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, Mack MJ, Voisine P, Krane M, Yerokun B, Bowdish ME, Conradi L, Bolling SF, Miller MA, Taddei-Peters WC, Jeffries NO, Parides MK, Weisel R, Jessup M, Rose EA, Mullen JC, Raymond S, Moquete EG, O'Sullivan K, Marks ME, Iribarne A, Beyersdorf F, Borger MA, Geirsson A, Bagiella E, Hung J, Gelijns AC, O'Gara PT, Ailawadi G.
PMID: 34767705
N Engl J Med. 2021 Nov 13; doi: 10.1056/NEJMoa2115961. Epub 2021 Nov 13.

BACKGROUND: Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or...

Cite
Gammie JS, Chu MWA, Falk V, et al. Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. N Engl J Med. 2021;doi: 10.1056/NEJMoa2115961.
Gammie, J. S., Chu, M. W. A., Falk, V., Overbey, J. R., Moskowitz, A. J., Gillinov, M., Mack, M. J., Voisine, P., Krane, M., Yerokun, B., Bowdish, M. E., Conradi, L., Bolling, S. F., Miller, M. A., Taddei-Peters, W. C., Jeffries, N. O., Parides, M. K., Weisel, R., Jessup, M., Rose, E. A., Mullen, J. C., Raymond, S., Moquete, E. G., O'Sullivan, K., Marks, M. E., Iribarne, A., Beyersdorf, F., Borger, M. A., Geirsson, A., Bagiella, E., Hung, J., Gelijns, A. C., O'Gara, P. T., Ailawadi, G. (2021). Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. The New England journal of medicine, . https://doi.org/10.1056/NEJMoa2115961
Gammie, James S, et al. "Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation." The New England journal of medicine vol. (2021). doi: https://doi.org/10.1056/NEJMoa2115961
Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, Mack MJ, Voisine P, Krane M, Yerokun B, Bowdish ME, Conradi L, Bolling SF, Miller MA, Taddei-Peters WC, Jeffries NO, Parides MK, Weisel R, Jessup M, Rose EA, Mullen JC, Raymond S, Moquete EG, O'Sullivan K, Marks ME, Iribarne A, Beyersdorf F, Borger MA, Geirsson A, Bagiella E, Hung J, Gelijns AC, O'Gara PT, Ailawadi G. Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. N Engl J Med. 2021 Nov 13; doi: 10.1056/NEJMoa2115961. Epub 2021 Nov 13. PMID: 34767705.
Copy Download .nbib Format: NLM
Repair or observe moderate ischemic mitral regurgitation during coronary artery bypass grafting? Prospective randomized multicenter data.

Annals of cardiothoracic surgery

Gulack BC, Englum BR, Castleberry AW, Daneshmand MA, Smith PK, Perrault LP.
PMID: 26309829
Ann Cardiothorac Surg. 2015 May;4(3):266-72. doi: 10.3978/j.issn.2225-319X.2015.04.02.

Ischemic mitral regurgitation (MR) is a common occurrence following myocardial infarction and its presence is associated with poor outcomes. The optimal treatment of ischemic MR is a matter of debate, especially for patients with moderate MR severity. Some authors...

Cite
Gulack BC, Englum BR, Castleberry AW, et al. Repair or observe moderate ischemic mitral regurgitation during coronary artery bypass grafting? Prospective randomized multicenter data. Ann Cardiothorac Surg. 2015;4(3):266-72doi: 10.3978/j.issn.2225-319X.2015.04.02.
Gulack, B. C., Englum, B. R., Castleberry, A. W., Daneshmand, M. A., Smith, P. K., & Perrault, L. P. (2015). Repair or observe moderate ischemic mitral regurgitation during coronary artery bypass grafting? Prospective randomized multicenter data. Annals of cardiothoracic surgery, 4(3), 266-72. https://doi.org/10.3978/j.issn.2225-319X.2015.04.02
Gulack, Brian C, et al. "Repair or observe moderate ischemic mitral regurgitation during coronary artery bypass grafting? Prospective randomized multicenter data." Annals of cardiothoracic surgery vol. 4,3 (2015): 266-72. doi: https://doi.org/10.3978/j.issn.2225-319X.2015.04.02
Gulack BC, Englum BR, Castleberry AW, Daneshmand MA, Smith PK, Perrault LP. Repair or observe moderate ischemic mitral regurgitation during coronary artery bypass grafting? Prospective randomized multicenter data. Ann Cardiothorac Surg. 2015 May;4(3):266-72. doi: 10.3978/j.issn.2225-319X.2015.04.02. PMID: 26309829; PMCID: PMC4533085.
Copy Download .nbib Format: NLM
Reply from authors: Discordant trial results lead to disproportionate learnings.

The Journal of thoracic and cardiovascular surgery

Mack MJ, O'Gara PT.
PMID: 33008572
J Thorac Cardiovasc Surg. 2022 Jan;163(1):e9-e10. doi: 10.1016/j.jtcvs.2020.09.018. Epub 2020 Sep 29.

No abstract available.

Cite
Mack MJ, O'Gara PT. Reply from authors: Discordant trial results lead to disproportionate learnings. J Thorac Cardiovasc Surg. 2020;163(1):e9-e10doi: 10.1016/j.jtcvs.2020.09.018.
Mack, M. J., & O'Gara, P. T. (2022). Reply from authors: Discordant trial results lead to disproportionate learnings. The Journal of thoracic and cardiovascular surgery, 163(1), e9-e10. https://doi.org/10.1016/j.jtcvs.2020.09.018
Mack, Michael J, and O'Gara, Patrick T. "Reply from authors: Discordant trial results lead to disproportionate learnings." The Journal of thoracic and cardiovascular surgery vol. 163,1 (2022): e9-e10. doi: https://doi.org/10.1016/j.jtcvs.2020.09.018
Mack MJ, O'Gara PT. Reply from authors: Discordant trial results lead to disproportionate learnings. J Thorac Cardiovasc Surg. 2022 Jan;163(1):e9-e10. doi: 10.1016/j.jtcvs.2020.09.018. Epub 2020 Sep 29. PMID: 33008572.
Copy Download .nbib Format: NLM
Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation.

The New England journal of medicine

Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, Mack MJ, Voisine P, Krane M, Yerokun B, Bowdish ME, Conradi L, Bolling SF, Miller MA, Taddei-Peters WC, Jeffries NO, Parides MK, Weisel R, Jessup M, Rose EA, Mullen JC, Raymond S, Moquete EG, O'Sullivan K, Marks ME, Iribarne A, Beyersdorf F, Borger MA, Geirsson A, Bagiella E, Hung J, Gelijns AC, O'Gara PT, Ailawadi G.
PMID: 34767705
N Engl J Med. 2021 Nov 13; doi: 10.1056/NEJMoa2115961. Epub 2021 Nov 13.

BACKGROUND: Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or...

Cite
Gammie JS, Chu MWA, Falk V, et al. Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. N Engl J Med. 2021;doi: 10.1056/NEJMoa2115961.
Gammie, J. S., Chu, M. W. A., Falk, V., Overbey, J. R., Moskowitz, A. J., Gillinov, M., Mack, M. J., Voisine, P., Krane, M., Yerokun, B., Bowdish, M. E., Conradi, L., Bolling, S. F., Miller, M. A., Taddei-Peters, W. C., Jeffries, N. O., Parides, M. K., Weisel, R., Jessup, M., Rose, E. A., Mullen, J. C., Raymond, S., Moquete, E. G., O'Sullivan, K., Marks, M. E., Iribarne, A., Beyersdorf, F., Borger, M. A., Geirsson, A., Bagiella, E., Hung, J., Gelijns, A. C., O'Gara, P. T., Ailawadi, G. (2021). Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. The New England journal of medicine, . https://doi.org/10.1056/NEJMoa2115961
Gammie, James S, et al. "Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation." The New England journal of medicine vol. (2021). doi: https://doi.org/10.1056/NEJMoa2115961
Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, Mack MJ, Voisine P, Krane M, Yerokun B, Bowdish ME, Conradi L, Bolling SF, Miller MA, Taddei-Peters WC, Jeffries NO, Parides MK, Weisel R, Jessup M, Rose EA, Mullen JC, Raymond S, Moquete EG, O'Sullivan K, Marks ME, Iribarne A, Beyersdorf F, Borger MA, Geirsson A, Bagiella E, Hung J, Gelijns AC, O'Gara PT, Ailawadi G. Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. N Engl J Med. 2021 Nov 13; doi: 10.1056/NEJMoa2115961. Epub 2021 Nov 13. PMID: 34767705.
Copy Download .nbib Format: NLM
Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation.

The New England journal of medicine

Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, Mack MJ, Voisine P, Krane M, Yerokun B, Bowdish ME, Conradi L, Bolling SF, Miller MA, Taddei-Peters WC, Jeffries NO, Parides MK, Weisel R, Jessup M, Rose EA, Mullen JC, Raymond S, Moquete EG, O'Sullivan K, Marks ME, Iribarne A, Beyersdorf F, Borger MA, Geirsson A, Bagiella E, Hung J, Gelijns AC, O'Gara PT, Ailawadi G.
PMID: 34767705
N Engl J Med. 2021 Nov 13; doi: 10.1056/NEJMoa2115961. Epub 2021 Nov 13.

BACKGROUND: Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or...

Cite
Gammie JS, Chu MWA, Falk V, et al. Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. N Engl J Med. 2021;doi: 10.1056/NEJMoa2115961.
Gammie, J. S., Chu, M. W. A., Falk, V., Overbey, J. R., Moskowitz, A. J., Gillinov, M., Mack, M. J., Voisine, P., Krane, M., Yerokun, B., Bowdish, M. E., Conradi, L., Bolling, S. F., Miller, M. A., Taddei-Peters, W. C., Jeffries, N. O., Parides, M. K., Weisel, R., Jessup, M., Rose, E. A., Mullen, J. C., Raymond, S., Moquete, E. G., O'Sullivan, K., Marks, M. E., Iribarne, A., Beyersdorf, F., Borger, M. A., Geirsson, A., Bagiella, E., Hung, J., Gelijns, A. C., O'Gara, P. T., Ailawadi, G. (2021). Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. The New England journal of medicine, . https://doi.org/10.1056/NEJMoa2115961
Gammie, James S, et al. "Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation." The New England journal of medicine vol. (2021). doi: https://doi.org/10.1056/NEJMoa2115961
Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, Mack MJ, Voisine P, Krane M, Yerokun B, Bowdish ME, Conradi L, Bolling SF, Miller MA, Taddei-Peters WC, Jeffries NO, Parides MK, Weisel R, Jessup M, Rose EA, Mullen JC, Raymond S, Moquete EG, O'Sullivan K, Marks ME, Iribarne A, Beyersdorf F, Borger MA, Geirsson A, Bagiella E, Hung J, Gelijns AC, O'Gara PT, Ailawadi G. Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. N Engl J Med. 2021 Nov 13; doi: 10.1056/NEJMoa2115961. Epub 2021 Nov 13. PMID: 34767705.
Copy Download .nbib Format: NLM
Risk for non-home discharge following surgery for ischemic mitral valve disease.

The Journal of thoracic and cardiovascular surgery

Lala A, Chang HL, Liu X, Charles EJ, Yerokun BA, Bowdish ME, Thourani VH, Mack MJ, Miller MA, O'Gara PT, Blackstone EH, Moskowitz AJ, Gelijns AC, Mullen JC, Stevenson LW.
PMID: 32307181
J Thorac Cardiovasc Surg. 2021 Dec;162(6):1769-1778.e7. doi: 10.1016/j.jtcvs.2020.02.084. Epub 2020 Mar 04.

OBJECTIVES: To determine the frequency and risk factors for non-home discharge (NHD) and its association with clinical outcomes and quality of life (QOL) at 1 year following cardiac surgery in patients with ischemic mitral regurgitation (IMR).METHODS: Discharge disposition was...

Cite
Lala A, Chang HL, Liu X, et al. Risk for non-home discharge following surgery for ischemic mitral valve disease. J Thorac Cardiovasc Surg. 2020;162(6):1769-1778.e7doi: 10.1016/j.jtcvs.2020.02.084.
Lala, A., Chang, H. L., Liu, X., Charles, E. J., Yerokun, B. A., Bowdish, M. E., Thourani, V. H., Mack, M. J., Miller, M. A., O'Gara, P. T., Blackstone, E. H., Moskowitz, A. J., Gelijns, A. C., Mullen, J. C., Stevenson, L. W. (2021). Risk for non-home discharge following surgery for ischemic mitral valve disease. The Journal of thoracic and cardiovascular surgery, 162(6), 1769-1778.e7. https://doi.org/10.1016/j.jtcvs.2020.02.084
Lala, Anuradha, et al. "Risk for non-home discharge following surgery for ischemic mitral valve disease." The Journal of thoracic and cardiovascular surgery vol. 162,6 (2021): 1769-1778.e7. doi: https://doi.org/10.1016/j.jtcvs.2020.02.084
Lala A, Chang HL, Liu X, Charles EJ, Yerokun BA, Bowdish ME, Thourani VH, Mack MJ, Miller MA, O'Gara PT, Blackstone EH, Moskowitz AJ, Gelijns AC, Mullen JC, Stevenson LW. Risk for non-home discharge following surgery for ischemic mitral valve disease. J Thorac Cardiovasc Surg. 2021 Dec;162(6):1769-1778.e7. doi: 10.1016/j.jtcvs.2020.02.084. Epub 2020 Mar 04. PMID: 32307181; PMCID: PMC7874266.
Copy Download .nbib Format: NLM
Reply: Discordant trial results lead to disproportionate learnings.

The Journal of thoracic and cardiovascular surgery

Mack MJ, O'Gara PT.
PMID: 33008572
J Thorac Cardiovasc Surg. 2020 Sep 29; doi: 10.1016/j.jtcvs.2020.09.018. Epub 2020 Sep 29.

No abstract available.

Cite
Mack MJ, O'Gara PT. Reply: Discordant trial results lead to disproportionate learnings. J Thorac Cardiovasc Surg. 2020;doi: 10.1016/j.jtcvs.2020.09.018.
Mack, M. J., & O'Gara, P. T. (2020). Reply: Discordant trial results lead to disproportionate learnings. The Journal of thoracic and cardiovascular surgery, . https://doi.org/10.1016/j.jtcvs.2020.09.018
Mack, Michael J, and O'Gara, Patrick T. "Reply: Discordant trial results lead to disproportionate learnings." The Journal of thoracic and cardiovascular surgery vol. (2020). doi: https://doi.org/10.1016/j.jtcvs.2020.09.018
Mack MJ, O'Gara PT. Reply: Discordant trial results lead to disproportionate learnings. J Thorac Cardiovasc Surg. 2020 Sep 29; doi: 10.1016/j.jtcvs.2020.09.018. Epub 2020 Sep 29. PMID: 33008572.
Copy Download .nbib Format: NLM
Repair or replace for severe ischemic mitral regurgitation: prospective randomized multicenter data.

Annals of cardiothoracic surgery

LaPar DJ, Acker MA, Gelijns AC, Kron IL.
PMID: 26539344
Ann Cardiothorac Surg. 2015 Sep;4(5):411-6. doi: 10.3978/j.issn.2225-319X.2015.04.11.

Ischemic mitral regurgitation (IMR) is a subset of functional mitral regurgitation (MR) that has the potential to impact an increasing number of patients in the future. This is in the context of a worldwide population, which continues to live...

Cite
LaPar DJ, Acker MA, Gelijns AC, et al. Repair or replace for severe ischemic mitral regurgitation: prospective randomized multicenter data. Ann Cardiothorac Surg. 2015;4(5):411-6doi: 10.3978/j.issn.2225-319X.2015.04.11.
LaPar, D. J., Acker, M. A., Gelijns, A. C., & Kron, I. L. (2015). Repair or replace for severe ischemic mitral regurgitation: prospective randomized multicenter data. Annals of cardiothoracic surgery, 4(5), 411-6. https://doi.org/10.3978/j.issn.2225-319X.2015.04.11
LaPar, Damien J, et al. "Repair or replace for severe ischemic mitral regurgitation: prospective randomized multicenter data." Annals of cardiothoracic surgery vol. 4,5 (2015): 411-6. doi: https://doi.org/10.3978/j.issn.2225-319X.2015.04.11
LaPar DJ, Acker MA, Gelijns AC, Kron IL. Repair or replace for severe ischemic mitral regurgitation: prospective randomized multicenter data. Ann Cardiothorac Surg. 2015 Sep;4(5):411-6. doi: 10.3978/j.issn.2225-319X.2015.04.11. PMID: 26539344; PMCID: PMC4598462.
Copy Download .nbib Format: NLM
Incorrect Unit of Measure.

JAMA

[No authors listed]
PMID: 31479120
JAMA. 2019 Sep 03;322(9):895. doi: 10.1001/jama.2019.12207.

No abstract available.

Cite
Incorrect Unit of Measure. JAMA. 2019;322(9):895doi: 10.1001/jama.2019.12207.
(2019). Incorrect Unit of Measure. JAMA, 322(9), 895. https://doi.org/10.1001/jama.2019.12207
"Incorrect Unit of Measure." JAMA vol. 322,9 (2019): 895. doi: https://doi.org/10.1001/jama.2019.12207
Incorrect Unit of Measure. JAMA. 2019 Sep 03;322(9):895. doi: 10.1001/jama.2019.12207. PMID: 31479120; PMCID: PMC6724418.
Copy Download .nbib Format: NLM
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).

medRxiv : the preprint server for health sciences

Murray DD, Babiker AG, Baker JV, Barkauskas CE, Brown SM, Chang CC, Davey VJ, Gelijns AC, Ginde AA, Grund B, Higgs E, Hudson F, Kan VL, Lane HC, Murray TA, Paredes R, Parmar MKB, Pett S, Phillips AN, Polizzotto MN, Reilly C, Sandkovsky U, Sharma S, Teitelbaum M, Thompson BT, Young BE, Neaton JD, Lundgren JD.
PMID: 33215168
medRxiv. 2021 Apr 08; doi: 10.1101/2020.11.08.20227876.

BACKGROUND: Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership initiated the Therapeutics for Inpatients with COVID-19 (TICO). TICO is a multi-arm, multi-stage...

Cite
Murray DD, Babiker AG, Baker JV, et al. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). medRxiv. 2021;doi: 10.1101/2020.11.08.20227876.
Murray, D. D., Babiker, A. G., Baker, J. V., Barkauskas, C. E., Brown, S. M., Chang, C. C., Davey, V. J., Gelijns, A. C., Ginde, A. A., Grund, B., Higgs, E., Hudson, F., Kan, V. L., Lane, H. C., Murray, T. A., Paredes, R., Parmar, M. K. B., Pett, S., Phillips, A. N., Polizzotto, M. N., Reilly, C., Sandkovsky, U., Sharma, S., Teitelbaum, M., Thompson, B. T., Young, B. E., Neaton, J. D., & Lundgren, J. D. (2021). Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.11.08.20227876
Murray, Daniel D, et al. "Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2020.11.08.20227876
Murray DD, Babiker AG, Baker JV, Barkauskas CE, Brown SM, Chang CC, Davey VJ, Gelijns AC, Ginde AA, Grund B, Higgs E, Hudson F, Kan VL, Lane HC, Murray TA, Paredes R, Parmar MKB, Pett S, Phillips AN, Polizzotto MN, Reilly C, Sandkovsky U, Sharma S, Teitelbaum M, Thompson BT, Young BE, Neaton JD, Lundgren JD. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). medRxiv. 2021 Apr 08; doi: 10.1101/2020.11.08.20227876. PMID: 33215168; PMCID: PMC7675662.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries